Literature DB >> 35837178

Perioperative lymphocyte-to-monocyte ratio changes plus CA199 in predicting the prognosis of patients with gastric cancer.

Wenjing Zhao1, Guoxin Mao2, Yueyue Zhu2.   

Abstract

Background: This study aimed to investigate the value of perioperative lymphocyte-to-monocyte ratio (LMR) changes in predicting postoperative survival among patients undergoing radical gastrectomy, and explore whether the combination of preoperative carbohydrate antigen 199 (CA199) and LMR changes would further improve the prognostic accuracy.
Methods: A total of 456 patients who underwent radical gastrectomy at the Affiliated Hospital of Nantong University were included as the training set, and 210 patients from the Nantong Tumor Hospital were enrolled as the validation set. The patients' peripheral complete blood counts, including lymphocytes, monocytes, and tumor marker CA199 level, were checked regularly in all patients 1 week before and after radical gastrectomy by two technicians who were blinded to their clinical characteristics. The LMR was calculated by dividing the lymphocyte count by the monocyte count in the peripheral blood. ΔLMR could be obtained by subtracting the preoperative LMR from the postoperative LMR. The serum CA199 level was determined through a latex immunoassay (Mitsubishi Chemical Ltd., Japan). The survival curve was drawn according to the Kaplan-Meier method, and variables with P<0.05 in univariate analyses were transferred to multivariate Cox regression analysis. A nomogram was constructed using the finalized separated prognostic factors of gastric cancer (GC). The main prognostic indicator was overall survival (OS).
Results: In the training and validation sets, the prognostic predictive ability of CA199 and ΔLMR (postoperative LMR minus preoperative LMR) was independently evaluated (both P<0.05). ΔLMR and CA199 were used to establish the ΔLMR-CA199 score. The results showed that the higher the ΔLMR-CA199 risk score, the worse the prognosis, especially in patients with advanced GC. Postoperative adjuvant chemotherapy improved the long-term prognosis of patients with a ΔLMR-CA199 score of 1 but had no significant effect on the survival rate of patients with 0 and 2 points. Conclusions: ΔLMR-CA199 can better predict the long-time survival of patients with GC. In addition, it can also predict the response of postoperative adjuvant chemotherapy in patients with GC. 2022 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Gastric cancer (GC); carbohydrate antigen 199 (CA199); curative gastrectomy; nomogram; prognosis

Year:  2022        PMID: 35837178      PMCID: PMC9274071          DOI: 10.21037/jgo-22-411

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  31 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group.

Authors:  C Compton; C M Fenoglio-Preiser; N Pettigrew; L P Fielding
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

3.  Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Jaffer A Ajani; Thomas A D'Amico; Khaldoun Almhanna; David J Bentrem; Joseph Chao; Prajnan Das; Crystal S Denlinger; Paul Fanta; Farhood Farjah; Charles S Fuchs; Hans Gerdes; Michael Gibson; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kimberly L Johung; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; Stephen Leong; Catherine Linn; A Craig Lockhart; Quan P Ly; Mary F Mulcahy; Mark B Orringer; Kyle A Perry; George A Poultsides; Walter J Scott; Vivian E Strong; Mary Kay Washington; Benny Weksler; Christopher G Willett; Cameron D Wright; Debra Zelman; Nicole McMillian; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2016-10       Impact factor: 11.908

Review 4.  The role of CD4+ T cell responses in antitumor immunity.

Authors:  D M Pardoll; S L Topalian
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

5.  Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients.

Authors:  Ying-Jian Song; Li-Xin Wang; Yong-Qing Hong; Zheng-Hong Lu; Qiang Tong; Xiao-Zheng Fang; Juan Tan
Journal:  Tumour Biol       Date:  2015-11-11

6.  Dynamic Changes in Pre- and Postoperative Levels of Inflammatory Markers and Their Effects on the Prognosis of Patients with Gastric Cancer.

Authors:  Jian-Xian Lin; Zu-Kai Wang; Ying-Qi Huang; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Qi-Yue Chen; Mi Lin; Ru-Hong Tu; Ze-Ning Huang; Ju-Li Lin; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  J Gastrointest Surg       Date:  2020-02-03       Impact factor: 3.452

7.  Elevated NLR May Be a Feature of Pediatric Brain Cancer Patients.

Authors:  Michal Yalon; Amos Toren; Dina Jabarin; Edna Fadida; Shlomi Constantini; Ruty Mehrian-Shai
Journal:  Front Oncol       Date:  2019-04-30       Impact factor: 6.244

8.  The Prognostic Role of the Platelet-Lymphocytes Ratio in Gastric Cancer: A Meta-Analysis.

Authors:  Zhengshui Xu; Wei Xu; Hua Cheng; Wei Shen; Jiaqi Ying; Fei Cheng; Wenji Xu
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

9.  Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma.

Authors:  Wei Wang; Xiao-Long Chen; Shen-Yu Zhao; Yu-Hui Xu; Wei-Han Zhang; Kai Liu; Xin-Zu Chen; Kun Yang; Bo Zhang; Zhi-Xin Chen; Jia-Ping Chen; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Oncotarget       Date:  2016-06-07

10.  Preoperative lymphocyte-to-monocyte ratio as a strong predictor of survival and recurrence for gastric cancer after radical-intent surgery.

Authors:  Jun-Peng Lin; Jian-Xian Lin; Long-Long Cao; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Qi-Yue Chen; Mi Lin; Ru-Hong Tu; Chang-Ming Huang
Journal:  Oncotarget       Date:  2017-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.